ES2351581T3 - Análogos del apogosipol para su utilización en el tratamiento del cáncer. - Google Patents

Análogos del apogosipol para su utilización en el tratamiento del cáncer. Download PDF

Info

Publication number
ES2351581T3
ES2351581T3 ES08003839T ES08003839T ES2351581T3 ES 2351581 T3 ES2351581 T3 ES 2351581T3 ES 08003839 T ES08003839 T ES 08003839T ES 08003839 T ES08003839 T ES 08003839T ES 2351581 T3 ES2351581 T3 ES 2351581T3
Authority
ES
Spain
Prior art keywords
alkyl
cancer
group
toxin
bcl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES08003839T
Other languages
English (en)
Spanish (es)
Inventor
John C. Reed
Maurizio Pellecchia
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Sanford Burnham Prebys Medical Discovery Institute
Original Assignee
Sanford Burnham Prebys Medical Discovery Institute
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanford Burnham Prebys Medical Discovery Institute filed Critical Sanford Burnham Prebys Medical Discovery Institute
Application granted granted Critical
Publication of ES2351581T3 publication Critical patent/ES2351581T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/02—Halogenated hydrocarbons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/225—Polycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Emergency Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
ES08003839T 2003-06-25 2004-06-25 Análogos del apogosipol para su utilización en el tratamiento del cáncer. Expired - Lifetime ES2351581T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48288603P 2003-06-25 2003-06-25
US482886P 2003-06-25

Publications (1)

Publication Number Publication Date
ES2351581T3 true ES2351581T3 (es) 2011-02-08

Family

ID=34102647

Family Applications (2)

Application Number Title Priority Date Filing Date
ES08003839T Expired - Lifetime ES2351581T3 (es) 2003-06-25 2004-06-25 Análogos del apogosipol para su utilización en el tratamiento del cáncer.
ES04777151T Active ES2303096T7 (es) 2003-06-25 2004-06-25 Derivados del catecol para el tratamiento del cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES04777151T Active ES2303096T7 (es) 2003-06-25 2004-06-25 Derivados del catecol para el tratamiento del cancer.

Country Status (13)

Country Link
US (3) US7812058B2 (https=)
EP (2) EP1653943B3 (https=)
JP (2) JP2007524633A (https=)
AT (2) ATE478663T1 (https=)
AU (1) AU2004258867B2 (https=)
CA (1) CA2529507C (https=)
DE (2) DE602004012279T3 (https=)
DK (1) DK1653943T4 (https=)
ES (2) ES2351581T3 (https=)
PL (1) PL1653943T6 (https=)
PT (1) PT1653943E (https=)
SI (1) SI1653943T1 (https=)
WO (1) WO2005009434A2 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7432304B2 (en) 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
WO2003038060A2 (en) * 2001-11-01 2003-05-08 The Regents Of The University Of Michigan Small molecule inhibitors targeted at bcl-2
JP2007524633A (ja) 2003-06-25 2007-08-30 ザ バーナム インスティチュート 癌細胞におけるアポトーシスの誘導のための化合物および方法
EP1732529A4 (en) * 2004-03-25 2009-02-25 Univ Michigan GOSSYPOL KOKRISTALLE AND ITS USE
US20060144723A1 (en) * 2004-11-02 2006-07-06 Mary Fuller Device for securing valuables
EP2197273B1 (en) * 2007-10-01 2014-09-24 Ascenta Therapeutics, Inc. Process for preparing r-gossypol l-phenylalaninol dienamine
US8039668B2 (en) 2008-10-17 2011-10-18 Burnham Institute For Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
EP2205088B1 (en) * 2007-10-19 2018-02-21 Burnham Institute for Medical Research Naphthalene-based inhibitors of anti-apoptotic proteins
FR2924712B1 (fr) 2007-12-06 2012-12-21 Univ Maine Derives du gossypol et de l'apogossypol, leurs preparations et leurs applications
GB0725077D0 (en) * 2007-12-21 2008-01-30 Univ Murcia Antifolate com[ounds for the treatment of melanoma
WO2009126172A1 (en) * 2008-04-11 2009-10-15 The Trustees Of Columbia University In The City Of New York Resistance to polyphenon e due to increased bcl-2 expression
CA2733930A1 (en) * 2008-08-14 2010-02-18 The Uab Research Foundation Anti-arrhythmia agents, methods of their use, methods of their identification, and kits therefore
US8487131B2 (en) 2009-04-15 2013-07-16 Sanford-Burnham Medical Research Institute Optically pure apogossypol derivative as pan-active inhibitor of anti-apoptotic B-cell lymphoma/leukemia-2 (BCL-2)
WO2011017096A2 (en) * 2009-08-04 2011-02-10 Mayo Foundation For Medical Education And Research Methods of treating hematologic cancers
AU2010303324A1 (en) 2009-10-08 2012-04-05 Sanford-Burnham Medical Research Institute Apogossypolone derivatives as anticancer agents
WO2014127191A1 (en) 2013-02-15 2014-08-21 The Regents Of The University Of Michigan Compositions and methods relating to hindering dot1l recruitment by mll-fusion proteins
US9180226B1 (en) 2014-08-07 2015-11-10 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US9655998B2 (en) 2014-08-07 2017-05-23 Cook Medical Technologies Llc Encapsulated drug compositions and methods of use thereof
US11241520B2 (en) 2014-08-07 2022-02-08 Cook Medical Technologies Llc Compositions and devices incorporating water-insoluble therapeutic agents and methods of the use thereof
US10195213B2 (en) 2015-03-13 2019-02-05 Unity Biotechnology, Inc. Chemical entities that kill senescent cells for use in treating age-related disease
JP2018512450A (ja) * 2015-03-19 2018-05-17 ウェンディ アン エプスタインＥＰＳＴＥＩＮ， Ｗｅｎｄｙ Ａｎｎｅ 女性の性的障害を治療するための化合物及び剤型
RU2654711C1 (ru) * 2017-07-10 2018-05-22 Федеральное государственное бюджетное научное учреждение "Томский национальный исследовательский медицинский центр Российской академии наук" (Томский НИМЦ) Средство, обладающее апоптоз-индуцирующей активностью
CN115281419B (zh) * 2018-04-20 2024-11-05 耐克创新有限合伙公司 带有板和中间流体填充囊的鞋底结构及其制造方法
CN110128290B (zh) * 2019-05-10 2022-04-29 江苏耐雀生物工程技术有限公司 红倍酚苯甲酰肼衍生物、中间体、制备方法及其应用
CA3155694A1 (en) * 2019-09-24 2021-04-01 Genetec Inc. Intermediary device for daisy chain and tree configuration in hybrid data/power connection

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4559157A (en) 1983-04-21 1985-12-17 Creative Products Resource Associates, Ltd. Cosmetic applicator useful for skin moisturizing
LU84979A1 (fr) 1983-08-30 1985-04-24 Oreal Composition cosmetique ou pharmaceutique sous forme aqueuse ou anhydre dont la phase grasse contient un polyether oligomere et polyethers oligomeres nouveaux
US4820508A (en) 1987-06-23 1989-04-11 Neutrogena Corporation Skin protective composition
US4992478A (en) 1988-04-04 1991-02-12 Warner-Lambert Company Antiinflammatory skin moisturizing composition and method of preparing same
US4938949A (en) 1988-09-12 1990-07-03 University Of New York Treatment of damaged bone marrow and dosage units therefor
US5385936A (en) * 1990-07-12 1995-01-31 The United States Of America As Represented By The Secretary Of The Department Of The Health And Human Services Gossypol acetic acid for the treatment of cancer
JPH1036260A (ja) * 1996-07-18 1998-02-10 Mitsui Norin Kk 抗ガン剤の効力増強方法
US5804567A (en) * 1996-07-18 1998-09-08 Cancer Institute (Hospital), Chinese Academy Of Medical Sciences Method of increasing the effectiveness of anti-metabolites
US6428818B1 (en) 1999-03-30 2002-08-06 Purdue Research Foundation Tea catechin formulations and processes for making same
US6608107B2 (en) * 2000-12-15 2003-08-19 Wackvom Limited Methods and compositions to treat conditions associated with neovascularization
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
WO2002097053A2 (en) * 2001-05-30 2002-12-05 The Regents Of The University Of Michigan Small molecule antagonists of bcl2 family proteins
JP2007524633A (ja) * 2003-06-25 2007-08-30 ザ バーナム インスティチュート 癌細胞におけるアポトーシスの誘導のための化合物および方法

Also Published As

Publication number Publication date
ATE387911T1 (de) 2008-03-15
ATE478663T1 (de) 2010-09-15
US20120269901A1 (en) 2012-10-25
DE602004012279T3 (de) 2010-07-15
AU2004258867B2 (en) 2010-02-18
PL1653943T3 (pl) 2008-09-30
EP1653943B1 (en) 2008-03-05
EP1938816B1 (en) 2010-08-25
EP1938816A2 (en) 2008-07-02
EP1653943B3 (en) 2008-07-30
DE602004012279T2 (de) 2009-07-16
DE602004028880D1 (de) 2010-10-07
DE602004012279T9 (de) 2010-01-28
WO2005009434A2 (en) 2005-02-03
US8367644B2 (en) 2013-02-05
CA2529507A1 (en) 2005-02-03
DK1653943T3 (da) 2008-06-23
US20050027000A1 (en) 2005-02-03
PL1653943T6 (pl) 2009-02-27
AU2004258867A1 (en) 2005-02-03
JP2007524633A (ja) 2007-08-30
EP1938816A3 (en) 2008-08-06
EP1653943A2 (en) 2006-05-10
US20110111057A1 (en) 2011-05-12
SI1653943T1 (sl) 2008-08-31
CA2529507C (en) 2011-08-09
ES2303096T3 (es) 2008-08-01
DE602004012279D1 (de) 2008-04-17
PT1653943E (pt) 2008-05-23
JP2012025767A (ja) 2012-02-09
US7812058B2 (en) 2010-10-12
WO2005009434A3 (en) 2005-06-09
DK1653943T4 (da) 2008-12-01
ES2303096T7 (es) 2009-06-18

Similar Documents

Publication Publication Date Title
ES2351581T3 (es) Análogos del apogosipol para su utilización en el tratamiento del cáncer.
Dei et al. Recent advances in the search of BCRP-and dual P-gp/BCRP-based multidrug resistance modulators
US7776894B2 (en) Compositions and methods for inhibiting growth and metastasis of melanoma
US20240342199A1 (en) Combination therapies targeting mitochondria for cancer therapy
ES2287029T3 (es) Composicion y procedimiento para modular la apoptosis en celulas que sobreexpresan proteinas miembro de la familia bcl-2.
CN110088210A (zh) 与酪氨酸激酶抑制剂结合使用的癌细胞增敏剂和增敏方法
JP2009506068A (ja) Ｈｉｆ阻害剤
Aneja et al. Rational design of the microtubule-targeting anti–breast cancer drug EM015
WO2012064897A2 (en) Bicyclic and tricyclic inhibitors of sumoylation enzymes and methods for their use
ES2763156T3 (es) Inducción apoptótica selectiva en células cancerosas incluyendo la activación de procaspasa-3
US7652033B2 (en) HIF-1 inhibitors
US20240207258A1 (en) Heterocyclic pdk1 inhibitors for use to treat cancer
CN106029070A (zh) 艾日布林和mTOR抑制剂作为治疗癌症的联合疗法的用途
BRPI0708307A2 (pt) combinação farmacêutica para administração simultánea, separada ou sequencial e usos de combinações farmacêuticas e de um inibidor do sìtio de fosforilação sobre os substratos de ck2 e um citostático farmaceuticamente aceitável
Niu et al. Novel carbazole sulfonamide microtubule-destabilizing agents exert potent antitumor activity against esophageal squamous cell carcinoma
AU731125B2 (en) Method for inducing death of neoplastic cells using piperazine oxirane derivatives
US11512073B2 (en) Benzimidazole derivatives, pharmaceutical composition comprising the same, and use thereof
Meng et al. Direct targeting of GLUT1 in cancer: A decade of inhibitor discovery and medicinal chemistry insights
US20260083724A1 (en) Compounds targeting pax3::foxo1 fusion protein
Scarpecci et al. Biological Activities of Synthetic Derivatives of Xanthones: An Update (2016-2020)
WO2013028866A1 (en) Therapeutic compounds and methods
EP3600433A1 (en) An agent that increases the expression of the bcl2-associated agonist of cell death for the treatment of cancer
HK1259985A1 (en) Heterocyclic pdk1 inhibitors for use to treat cancer
HK1259985B (en) Heterocyclic pdk1 inhibitors for use to treat cancer